Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Exelixis Sues MSN Pharmaceuticals, Asserts Patent Infringement

July 19, 2022, 9:36 PM

Exelixis says lawsuit arises from MSN’s further amendment of its abbreviated new drug application, originally filed with the FDA in 2019 for a generic version of Cabometyx (cabozantinib) tablets.

  • Says MSN’s ANDA now requests approval to market a generic version prior to expiration of Exelixis’ patent
  • NOTE: June 23, Exelixis’ Latest Cabometyx Patent Suit Is Down to Validity

NOTE

  • Exelixis Inc. shares were little changed in postmarket trading as of 5:32 p.m. New York time
    • The average 12-month price target of $27.08 is 24.0% above the current price
    • 11 buys, 2 sells, 2 holds

To view the source of this ...